Psychotropics in Pulmonary Disease – Psychiatry Education Forum

Course Information

Course Instructor

Dr. Harvinder Singh Author

The Pulmonary Framework

Respiratory reserve as the constraint: the two axes that govern everything

The smoking–CYP1A2 lever: starting, stopping, and the forced-quit toxicity trap

Respiratory depression & CNS-depressant stacking: benzodiazepines, Z-drugs, gabapentinoids, opioid co-prescription — the additive-burden math

Drug-Class Decision Guides

Antidepressants: the fluvoxamine–theophylline trap, the clean SSRIs/SNRIs, respiratory-safe first line

Antipsychotics: clozapine/olanzapine under the smoking lever, sedation/aspiration, QT stacked with pulmonary co-meds

Mood stabilizers: carbamazepine’s induction stacking on top of smoking, lithium–theophylline clearance, valproate sedation

Anxiolytics & the dyspnea–anxiety overlap: buspirone, non-benzo strategies, propranolol in reactive airways

Disease-State & Treatment-Driven Problems

Pulmonary drugs that cause psychiatric symptoms

Obstructive sleep apnea: sedation load, antipsychotic weight gain, what’s actually safe

Smoking-cessation pharmacotherapy in the psychiatric patient

COPD & the hypercapnic CO₂ retainer

Psychotropic-induced pulmonary toxicity & pulmonary hypertension

Advanced/end-stage disease & palliative dyspnea

Rapid-reference decision table

Rapid-reference decision table

Responses